INDIGO: a global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. - Van den Bent, Martin J.; Blumenthal, Deborah T.; Touat, Mehdi; Peters, Katherine B.; Clarke, Jennifer Leigh; Mendez, Joe Sammy; Welsh, Liam; Mason, Warren P.; Hottinger, Andreas Felix; Sanchez, Juan Manuel Sepulveda; Wick, Wolfgang; Soffietti, Riccardo; et al. (Journal of clinical oncology, 2023)
Gesehen am 02.08.2024